Liver cancer survival statistics

Age

Age that liver cancer survival is highest, 2009-2013, England

Five-year survival for liver cancer is generally higher in younger people and decreases with increasing age. Five-year net survival in men ranges from 23% in 15-39 year-olds to 6% in 80-99 year-olds for patients diagnosed with liver cancer in England during 2009-2013.[1] In women, five-year survival ranges from 30% to 2% in the same age groups.

Liver Cancer (C22), Five-Year Net Survival by Age, England, 2009-2013

See also

Liver cancer incidence statistics by age

Liver cancer mortality statistics by age

Cancer survival statistics by age for all cancers

References

  1. Office for National Statistics. Cancer survival in England: adults diagnosed in 2009 to 2013, followed up to 2014. Newport: ONS; 2015.

About this data

Data is for: England, 2009-2013, ICD-10 C22

Last reviewed:

Five-year relative survival for liver cancer in men in England (9%) is below the average for Europe (11%). Scotland (8%) is also below the European average but Wales (9%) and Northern Ireland (10%) are similar to the European average.[1] Across the European countries for which data available, five-year relative survival in men ranges from 3% (Bulgaria) to 16% (Belgium).[1] 

Five-year relative survival for liver cancer in women in England (8%) is below the average for Europe (13%). Scotland (7%) is also below the European average but Wales (8%) is similar to the European average.[1] No five-year survival data is available for Northern Ireland. Across the European countries for which data is available, five-year relative survival in women ranges from 5% (Slovenia) to 21% (Belgium).[1] 

Liver Cancer (C22), Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

See also

Cancer diagnosis and treatment

Liver cancer incidence

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, liver cancer (International Classification of Diseases for Oncology C22).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Cancer stats explained

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

 @CRUKHCPs

The University of Manchester are currently conducting a survey into healthcare professionals' and public attitudes towards sun exposure and vitamin D.

 Take part

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.